Hybridoma technology: Difference between revisions
m BOT - rv 216.221.81.98 (talk) to last version by 128.196.10.37 |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Hybridoma''' cells are cells that have been engineered to produce a desired antibody in large amounts. To produce [[monoclonal antibodies]], [[B-cells]] are removed from the spleen of an animal that has been challenged with the relevant antigen. These B-cells are then fused with [[myeloma]] tumor cells that can grow indefinitely in culture (myeloma is a B-cell cancer). This fusion is performed by making the cell membranes more permeable. The fused hybrid cells (called hybridomas), being cancer cells, will multiply rapidly and indefinitely and will produce large amounts of the desired antibodies. They have to be selected and subsequently cloned by limiting dilution. Supplemental media containing Interleukin-6 (such as [[briclone]]) are essential for this step. |
'''Hybridoma''' cells are cells that have been engineered to produce a desired antibody in large amounts. To produce [[monoclonal antibodies]], [[B-cells]] are removed from the spleen of an animal that has been challenged with the relevant antigen. These B-cells are then fused with [[myeloma]] tumor cells that can grow indefinitely in culture (myeloma is a B-cell cancer). This fusion is performed by making the cell membranes more permeable. The fused hybrid cells (called hybridomas), being cancer cells, will multiply rapidly and indefinitely and will produce large amounts of the desired antibodies. They have to be selected and subsequently cloned by limiting dilution. Supplemental media containing Interleukin-6 (such as [[briclone]]) are essential for this step. |
||
{{biotech-stub}} |
{{biotech-stub}} |
||
==Publications== |
|||
*[http://www.liebertpub.com/publication.aspx?pub_id=20 Hybridoma] publishes fully referred papers in the field of molecular immunology and experimental and clinical immunotherapy, including papers on the application of monoclonal antibodies for diagnostics and therapy. |
|||
Revision as of 16:22, 16 October 2006
Hybridoma cells are cells that have been engineered to produce a desired antibody in large amounts. To produce monoclonal antibodies, B-cells are removed from the spleen of an animal that has been challenged with the relevant antigen. These B-cells are then fused with myeloma tumor cells that can grow indefinitely in culture (myeloma is a B-cell cancer). This fusion is performed by making the cell membranes more permeable. The fused hybrid cells (called hybridomas), being cancer cells, will multiply rapidly and indefinitely and will produce large amounts of the desired antibodies. They have to be selected and subsequently cloned by limiting dilution. Supplemental media containing Interleukin-6 (such as briclone) are essential for this step.
 | This biotechnology article is a stub. You can help Wikipedia by expanding it. |
Publications
- Hybridoma publishes fully referred papers in the field of molecular immunology and experimental and clinical immunotherapy, including papers on the application of monoclonal antibodies for diagnostics and therapy.